UPMC Hillman Cancer Center | Strategic Alliance Partners

January 22, 2021

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

January 20, 2021

Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.

January 19, 2021

Alison R. Sehgal, MD, discusses some of the novel approaches that have been adopted into practice and ongoing research building on the advances that have been made with targeted therapy.

January 13, 2021

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

January 08, 2021

Phuong L. Mai, MD, discusses guidelines for genetic testing in colorectal cancer.

January 06, 2021

Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.